Ivosidenib,Venetoclax,gilteritinib,Selinexor

PreclinicalSmall molecule

IInstitute of Hematology & Blood Diseases Hospital, China

Ivosidenib,Venetoclax,gilteritinib,Selinexor is one of 69 small molecule programs targeting Acute Myeloid Leukemia. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Acute Myeloid LeukemiaActive, not recruiting

AMLRecruiting

Acute Myeloid LeukemiaPreclinical

Active, not recruiting

AMLPreclinical

Recruiting

Competition

Competitive Landscape

235 competitors in Acute Myeloid Leukemia

#DrugCompanyPhaseTrials

Novantrone

Pfizer

Phase 3

34 2

Xospata

Astellas

Phase 3

24 3

Fludara

Sanofi

Phase 3

18 4

Vepesid

AAvyxa

Phase 3

52 5

Cerubidine

HHikma Pharmaceuticals LLC

Phase 3

42 6

Vanflyta

Daiichi Sankyo

Phase 3

16 7

Mylotarg

WWyeth-Lederle Vaccines

Phase 3

38 8

Cerubidine

HHikma Pharmaceuticals LLC

Phase 3

32 9

Nexavar

Cellcept

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

PreclinicalRecruiting

AML

NCT06265545

Clinical

Trials by Indication[1]

AML1 trial

Multicenter, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid Leukemia

Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Preclinical·NCT06265545·458 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Ivosidenib,Venetoclax,gilteritinib,Selinexor. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ivosidenib,Venetoclax,gilteritinib,Selinexor compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ivosidenib,Venetoclax,gilteritinib,Selinexor. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Institute of Hematology & Blood Diseases Hospital, China company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: IInstitute of Hematology & Blood Diseases Hospital, China

Ivosidenib,Venetoclax,gilteritinib,Selinexor

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

AML1 trial

References

Drug Info

Quick Facts

Related News